Trillium Therapeutics (TRIL) Prices 10M Share Common Offering at $13/Sh

H.C. Wainwright Upgrades Trillium Therapeutics (TRIL) to Buy

H.C. Wainwright analyst Swayampakula Ramakanth upgraded Trillium Therapeutics (NASDAQ: TRIL) from Neutral to Buy.

For an analyst ratings summary and ratings history on Trillium Therapeutics click here. For more ratings news on Trillium Therapeutics click here.

Shares of Trillium Therapeutics closed at $12.94 yesterday.

Trillium Therapeutics (TRIL) Announces 8.5M Share Proposed Public Offering of Common Shares

Trillium Therapeutics Inc. (Trillium or the Company) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of up to 8,500,000 common shares (the Common Shares) of the Company (the Offering). In addition, Trillium intends to grant the underwriters a 30-day... More

Pre-Open Stock Movers 09/09: (TRIL) (NLS) (TSLA) Higher; (WORK) (ANTX) (LULU) Lower (more...)

Today's Pre-Open Stock Movers:

Trillium Therapeutics Inc. (NASDAQ: TRIL) 42.7% HIGHER; announced that it has agreed to sell 2,297,794 of its common shares at a price of $10.88 per share to Pfizer Inc. (NYSE: PFE), for gross proceeds of $25.0 million (the Transaction). The common shares were offered and sold to Pfizer Inc. in a registered direct offering conducted without an underwriter or placement agent. The offering is expected to close on or about September 10, 2020.

Slack (NYSE: WORK)... More

Trillium Therapeutics (TRIL) PT Raised to $24 at Ladenburg Thalmann

Ladenburg Thalmann analyst Wangzhi Li raised the price target on Trillium Therapeutics (NASDAQ: TRIL) to $24.00 (from $12.00) while maintaining a Buy rating.... More

Trillium Therapeutics (TRIL) PT Raised to $14 at JMP Securities

JMP Securities analyst Reni Benjamin raised the price target on Trillium Therapeutics (NASDAQ: TRIL) to $14.00 (from $10.00) while maintaining a Market Outperform rating.... More